A Randomized, Double-Blind, Placebo-Controlled Trial Protocol for a Chinese Herbal Medicine in Treating Liver Cancer Pain

Background

Liver cancer is a leading cause of cancer death globally, with hepatocellular carcinoma (HCC) being the most common type. Patients often suffer from moderate-to-severe pain, which is currently managed with opioids. However, long-term opioid use can lead to significant side effects and dependency issues. Traditional Chinese Medicine (TCM), specifically FZXLP, offers a potential alternative with fewer side effects and a focus on holistic treatment.

Methods

Design and Settings

This is a prospective, randomized, double-blind, placebo-controlled trial registered with the China Clinical Trials Registry. The study involves 72 participants, divided equally into an FZXLP group and a placebo group, to assess the efficacy and safety of FZXLP in combination with S-1 capsules.

Participants

Eligible participants are adults diagnosed with primary liver cancer experiencing pain, with specific inclusion and exclusion criteria to ensure the safety and relevance of the study.

Intervention

Participants in the treatment group receive FZXLP applied externally in combination with S-1 capsules, while the control group receives a placebo with S-1 capsules. The treatment duration is 21 days, with assessments conducted at various intervals to measure pain relief, quality of life, and safety.

Outcome Measures

The primary outcome is the reduction in pain, measured by changes in opioid use, pain scores, and the incidence of breakthrough cancer pain. Secondary outcomes include tumor progression, quality of life, and safety assessments.

Discussion

FZXLP represents a promising approach to managing liver cancer pain, potentially offering an effective alternative to opioids with fewer side effects. The study's rigorous design aims to provide reliable data on the efficacy and safety of FZXLP, contributing to the broader application of TCM in cancer care.

Clinical Trial Status

Recruitment began in November 2023, with the study expected to conclude by December 2025. This trial is a significant step towards integrating TCM into conventional cancer treatment protocols, offering hope for improved pain management strategies for liver cancer patients.